Sự kiệt sức của tế bào T trong nhiễm virus viêm gan B mãn tính: Kiến thức hiện tại và ý nghĩa lâm sàng

Li X, Liu X, Tian L, Chen Y . Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections. Clin Rev Allergy Immunol 2014; e-pub ahead of print 6 December 2014; doi:10.1007/s12016-014-8465-4.

Asabe S, Wieland SF, Chattopadhyay PK, Roederer M, Engle RE, Purcell RH et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 2009; 83: 9652–9662.

Zhang Z, Zhang JY, Wang LF, Wang FS . Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. J Gastroenterol Hepatol 2012; 27: 223–230.

Ferrari C . HBV and the immune response. Liver Int 2015; 35 (Suppl 1): 121–128.

Phillips S, Chokshi S, Riva A, Evans A, Williams R, Naoumov NV . CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol 2010; 184: 287–295.

Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 2009; 58: 974–982.

Bertoletti A, Gehring AJ . The immune response during hepatitis B virus infection. J Gen Virol 2006; 87: 1439–1449.

Wherry EJ . T cell exhaustion. Nat Immunol 2011; 12: 492–499.

Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS . The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000; 191: 1269–1280.

Lopes AR, Kellam P, Das A, Dunn C, Kwan A, Turner J et al. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest 2008; 118: 1835–1845.

Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007; 81: 4215–4225.

Yi JS, Cox MA, Zajac AJ . T-cell exhaustion: characteristics, causes and conversion. Immunology 2010; 129: 474–481.

Kim PS, Ahmed R . Features of responding T cells in cancer and chronic infection. Curr Opin Immunol 2010; 22: 223–230.

Mumprecht S, Schürch C, Schwaller J, Solenthaler M, Ochsenbein AF . Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 2009; 114: 1528–1536.

Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114: 1537–1544.

Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D et al. PD-1 Is a Regulator of NY-ESO-1-Specific CD8(+) T Cell Expansion in Melanoma Patients. J Immunol 2009; 182: 5240–5249.

Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167–3175.

Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682–687.

Homann D, Dummer W, Wolfe T, Rodrigo E, Theofilopoulos AN, Oldstone MB et al. Lack of intrinsic CTLA-4 expression has minimal effect on regulation of antiviral T-cell immunity. J Virol 2006; 80: 270–280.

Nakamoto N, Cho H, Shaked A, Olthoff K, Valiga ME, Kaminski M et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog 2009; 5: e1000313.

Cecchinato V, Tryniszewska E, Ma ZM, Vaccari M, Boasso A, Tsai WP et al. Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J Immunol 2008; 180: 5439–5447.

Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009; 458: 206–210.

Kao C, Oestreich KJ, Paley MA, Crawford A, Angelosanto JM, Ali MA et al. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat Immunol 2011; 12: 663–671.

Crawford A, Angelosanto JM, Kao C, Doering TA, Odorizzi PM, Barnett BE et al. Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection. Immunity 2014; 40: 289–302.

Chen L, Flies DB . Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013; 13: 227–242.

Raziorrouh B, Schraut W, Gerlach T, Nowack D, Grüner NH, Ulsenheimer A et al. The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology 2010; 52: 1934–1947.

Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009; 10: 29–37.

Bengsch B, Seigel B, Ruhl M, Timm J, Kuntz M, Blum HE et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 2010; 6: e1000947.

Bertoletti A, Costanzo A, Chisari FV, Levrero M, Artini M, Sette A et al. Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med 1994; 180: 933–943.

Porichis F, Kwon DS, Zupkosky J, Tighe DP, McMullen A, Brockman MA et al. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood 2011; 118: 965–974.

Protzer U, Maini MK, Knolle PA . Living in the liver: hepatic infections. Nat Rev Immunol 2012; 12: 201–213.

Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A 2004; 101: 10691–10696.

Okazaki T, Honjo T . The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27: 195–201.

Bengsch B, Martin B, Thimme R . Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J Hepatol 2014; 61: 1212–1219.

Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010; 138: 682–693.

Schurich A, Pallett LJ, Lubowiecki M, Singh HD, Gill US, Kennedy PT et al. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog 2013; 9: e1003208.

Yang PL, Althage A, Chung J, Chisari FV . Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci U S A 2002; 99: 13825–13830.

Tzeng HT, Tsai HF, Liao HJ, Lin YJ, Chen L, Chen PJ et al. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model. PLoS One 2012; 7: e39179.

Kurktschiev PD, Raziorrouh B, Schraut W, Backmund M, Wächtler M, Wendtner CM et al. Dysfunctional CD8(+) T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction. J Exp Med 2014; 211: 2047–2059.

Walunas TL, Bakker CY, Bluestone JA . CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996; 183: 2541–2550.

Krummel MF, Allison JP . CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996; 183: 2533–2540.

Fallarino F, Fields PE, Gajewski TF . B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Exp Med 1998; 188: 205–210.

Ise W, Kohyama M, Nutsch KM, Lee HM, Suri A, Unanue ER et al. CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol 2010; 11: 129–135.

Peggs KS, Quezada SA, Allison JP . Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 2008; 224: 141–165.

Graefe SE, Jacobs T, Wächter U, Bröker BM, Fleischer B . CTLA-4 regulates the murine immune response to Trypanosoma cruzi infection. Parasite Immunol 2004; 26: 19–28.

Zubairi S, Sanos SL, Hill S, Kaye PM . Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani. Eur J Immunol 2004; 34: 1433–1440.

Yu Y, Wu H, Tang Z, Zang G . CTLA4 silencing with siRNA promotes deviation of Th1/Th2 in chronic hepatitis B patients. Cell Mol Immunol 2009; 6: 123–127.

Thio CL, Mosbruger TL, Kaslow RA, Karp CL, Strathdee SA, Vlahov D et al. Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol 2004; 78: 11258–11262.

Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, Micco L et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 2011; 53: 1494–1503.

Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM et al. Reversal of the TCR stop signal by CTLA-4. Science 2006; 313: 1972–1975.

Keler T, Halk E, Vitale L, O'Neill T, Blanset D, Lee S et al. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J Immunol 2003; 171: 6251–6259.

Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013; 59: 81–88.

Kirkwood JM, Lorigan P, Hersey P, Hauschild A, Robert C, McDermott D et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 2010; 16: 1042–1048.

Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009; 27: 1075–1081.

Chung KY, Gore I, Fong L, Venook A, Beck SB, Dorazio P et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol 2010; 28: 3485–3490.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–723.

Kaufmann DE, Walker BD . PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol 2009; 182: 5891–5897.

Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007; 8: 1246–1254.

Shin H, Blackburn SD, Intlekofer AM, Kao C, Angelosanto JM, Reiner SL et al. A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity 2009; 31: 309–320.

Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6: 1245–1252.

Golden-Mason L, Palmer BE, Kassam N, Townshend-Bulson L, Livingston S, McMahon BJ et al. Negative Immune Regulator Tim-3 is overexpressed on T Cells in Hepatitis C Virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T Cells. J Virol 2009; 83: 9122–9130.

Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008; 205: 2763–2779.

Nebbia G, Peppa D, Schurich A, Khanna P, Singh HD, Cheng Y et al. Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One 2012; 7: e47648.

Ju Y, Hou N, Meng J, Wang X, Zhang X, Zhao D et al. T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J Hepatol 2010; 52: 322–329.

Wada J, Ota K, Kumar A, Wallner EI, Kanwar YS . Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin. J Clin Invest 1997; 99: 2452–2461.

Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2012; 56: 1342–1351.

Mengshol JA, Golden-Mason L, Arikawa T, Smith M, Niki T, McWilliams R et al. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One 2010; 5: e9504.

Sehrawat S, Suryawanshi A, Hirashima M, Rouse BT . Role of Tim-3/galectin-9 inhibitory interaction in viral-induced immunopathology: shifting the balance toward regulators. J Immunol 2009; 182: 3191–3201.

Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell R et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68–76.

Das A, Hoare M, Davies N, Lopes AR, Dunn C, Kennedy PT et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med 2008; 205: 2111–2124.

Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, Pantaleo G . HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci U S A 2005; 102: 7239–7244.

Bertoletti A, Maini MK . Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr Opin Microbiol 2000; 3: 387–392.

Maeda S, Chang L, Li ZW, Luo JL, Leffert H, Karin M . IKK beta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNF alpha. Immunity 2003; 19: 725–737.

Su F, Schneider RJ . Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. Proc Natl Acad sci U S A 1997; 94: 8744–8749.

Li L, Liu M, Cheng LW, Gao XY, Fu JJ, Kong G et al. HBcAg-specific IL-21-producing CD4+ T cells are associated with relative viral control in patients with chronic hepatitis B. Scand J Immunol 2013; 78: 439–446.

Yang PL, Althage A, Chung J, Maier H, Wieland S, Isogawa M et al. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A 2010; 107: 798–802.

Trautmann T, Kozik JH, Carambia A, Richter K, Lischke T, Schwinqe D et al. CD4+T-cell help is required for Effective CD8+T cell-Mediated resolution of acute viral hepatitis in mice. PLoS One 2014; 9: e86348.

Williams MA, Bevan MJ . Effector and memory CTL differentiation. Annu Rev Immunol 2007; 25: 171–192.

Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN . Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 2006; 440: 890–895.

Williams MA, Tyznik AJ, Bevan MJ . Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 2006; 441: 890–893.

Nakanishi Y, Lu B, Gerard C, Iwasaki A . CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 2009; 462: 510–513.

Ulsenheimer A, Gerlach JT, Gruener NH, Jung MC, Schirren CA, Schraut W et al. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology 2003; 37: 1189–1198.

Rangachari M, Zhu C, Sakuishi K, Xiao S, Karman J, Chen A et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. Nat Med 2012; 18: 1394–1400.

Antoine P, Olislagers V, Huygens A, Lecomte S, Liesnard C, Donner C et al. Functional exhaustion of CD4+ T lymphocytes during primary cytomegalovirus infection. J Immunol 2012; 189: 2665–2672.

Raziorrouh B, Heeq M, Kurktschiev P, Schraut W, Zachoval R, Wendtner C et al. Inhibitory phenotype of HBV-specific CD4+ T-cells is characterized by high PD-1 expression but absent coregulation of multiple inhibitory molecules. PLoS One 2014; 9: e105703.

Raziorrouh B, Ulsenheimer A, Schraut W, Heep M, Kurktschiev P, Zachoval R et al. Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection. Gastroenterology 2011; 141: 1422–1431.

Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, Kasprowicz V, Nolan BE, Streeck H et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med 2012; 209: 61–75.

Kassu A, Marcus RA, D'Souza MB, Kelly-McKnight EA, Golden-Mason L, Akkina R et al. Regulation of virus-specific CD4+ T cell function by multiple costimulatory receptors during chronic HIV infection. J Immunol 2010; 185: 3007–3018.

Rybakova KN, Tomaszewska A, van Mourik S, Blom J, Westerhoff HV, Carlberg C et al. Tracing the molecular basis of transcriptional dynamics in noisy data by using an experiment-based mathematical model. Nucleic Acids Res 2015; 43: 153–161.

Ferri S, Longhi MS, De Molo C, Lalanne C, Muratori P, Granito A et al. A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology 2010; 52: 999–1007.

Xu L, Da L, Plouffe SW, Chong J, Kool E, Wang D . Molecular basis of transcriptional fidelity and DNA lesion-induced transcriptional mutagenesis. DNA Repair (Amst) 2014; 19: 71–83.

Schuchardt BJ, Bhat V, Mikles DC, McDonald CB, Sudol M, Farooq A . Molecular basis of the binding of YAP transcriptional regulator to the ErbB4 receptor tyrosine kinase. Biochimie 2014; 101: 192–202.

Alatrakchi N, Graham CS, van der Vliet HJ, Sherman KE, Exley MA, Koziel MJ . Hepatitis C virus (HCV)-specific CD8(+) cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses. J Virol 2007; 81: 5882–5892.

Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41: 771–778.

Yang G, Liu A, Xie Q, Guo TB, Wan B, Zhou B et al. Association of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B. Int Immunol 2007; 19: 133–140.

Franzese O, Kennedy PT, Gehring AJ, Gotto J, Williams R, Maini MK et al. Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol 2005; 79: 3322–3328.

Stoop JN, Claassen MA, Woltman AM, Binda RS, Kuipers EJ, Janssen HL et al. Intrahepatic regulatory T cells are phenotypically distinct from their peripheral counterparts in chronic HBV patients. Clin Immunol 2008; 129: 419–427.

Claassen MA, de Knegt RJ, Turgut D, Groothuismink ZM, Janssen HL, Boonstra A . Negative regulation of hepatitis C virus specific immunity is highly heterogeneous and modulated by pegylated interferon-alpha/ribavirin therapy. PLoS One 2012; 7: e49389.

Maier H, Isogawa M, Freeman GJ, Chisari FV . PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol 2007; 178: 2714–2720.

Paley MA, Kroy DC, Odorizzi PM, Johnnidis JB, Dolfi DV, Barnett BE et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 2012; 338: 1220–1225.

Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007; 27: 670–684.

Collins MH, Henderson AJ . Transcriptional regulation and T cell exhaustion. Curr Opin HIV AIDS 2014; 9: 459–463.

Kwon H, Thierry-Mieg D, Thierry-Mieg J, Kim HP, Oh J, Tunyaplin C et al. Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity 2009; 31: 941–952.

Subleski JJ, Jiang Q, Weiss JM, Wiltrout RH . The split personality of NKT cells in malignancy, autoimmune and allergic disorders. Immunotherapy 2011; 3: 1167–1184.

La Cava A, Van Kaer L . Fu-Dong-Shi. CD4+CD25+ Tregs and NKT cells: regulators regulating regulators. Trends Immunol 2006; 27: 322–327.

Chen CF, Feng X, Liao HY, Jin WJ, Zhang J, Wang Y et al. Regulation of T cell proliferation by JMJD6 and PDGF-BB during chronic hepatitis B infection. Sci Rep 2014; 4: 6359.

Raziorrouh B, Heeg M, Kurktschiev P, Schraut W, Zachoval R1, Wendtner C et al. Inhibitory phenotype of HBV-specific CD4+ T-cells is characterized by high PD-1 expression but absent coregulation of multiple inhibitory molecules. PLoS One 2014; 9: e105703.